Catalent, Inc. (CTLT)
| Market Cap | 19.48B |
| Revenue (ttm) | 3.28B |
| Net Income (ttm) | 249.20M |
| Shares Out | 164.14M |
| EPS (ttm) | 1.58 |
| PE Ratio | 74.77 |
| Forward PE | 46.08 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $118.28 |
| Previous Close | $119.67 |
| Change ($) | -1.39 |
| Change (%) | -1.16% |
| Day's Open | 119.70 |
| Day's Range | 117.54 - 119.97 |
| Day's Volume | 580,161 |
| 52-Week Range | 36.95 - 119.97 |
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene...
Catalent is forming a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Feb. 3. The post Earnings Season Preview: Catalent Near Buy Zone With...
Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...
Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.
Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.
On Friday, Catalent got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Catalent Joins Rank Of Stocks With 95-Plus Composite Rating appeared first on Investor's Bus...
Catalent Inc (NYSE: CTLT) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets. The Catalent Analyst: Paul Knig...
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
Final Trades: Deere, Host Hotels, Retail & more
The "Halftime Report" traders give their top picks to watch for the second half.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...
Each week, Benzinga will examine a stock that might be considered a little under the radar. You may have never heard of the company before, but chances are you're pretty familiar with the line...
Catalent, Inc. (CTLT) CEO John Chiminski on Q1 2021 Results - Earnings Call Transcript
Catalent (CTLT) delivered earnings and revenue surprises of 13.16% and 4.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...
REGULATED INFORMATION
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...
In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks...
Etsy (ETSY), Catalent (CTLT), and Teradyne (TER) will join the index on Sept. 21.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
NEW YORK, Sept. 4, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriat...
Some Tesla investors expected the company to be included this quarter, as the company recently reported its fourth consecutive quarter of profitability.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.
Catalent, Inc. (CTLT) CEO John Chiminski on Q4 2020 Results - Earnings Call Transcript
IBD Stock Of The Day Catalent has inked Covid vaccine manufacturing deals with AstraZeneca, Johnson & Johnson and Moderna, riding those contracts to record highs. It also beat Q4 goals.
Before the opening bell on Aug. 31, Catalent Inc. (NYSE:CTLT), a multinational corporation headquartered in Somerset, New Jersey, released its fourth-quarter financial results.
Catalent (NYSE: CTLT) shares are trading higher on Monday after the company reported better-than-expected fourth-quarter EPS and sales results.
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 0.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Catalent (NYSE:CTLT) rose 2.7% in pre-market trading after the company reported Q4 results.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.
The Race To Erase COVID-19
SOMERSET, N.J. & BURLINGAME, Calif.
This company will make money from Moderna's COVID-19 vaccine even if Moderna doesn't.
Bullish chart patterns suggest that the the mid-cap growth market segment is worth watching over the weeks and months ahead.
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
Moderna Inc (NASDAQ: MRNA), a frontrunner in the COVID-19 vaccine race, announced a manufacturing collaboration agreement Thursday with contract development and manufacturing organization Cata...
Moderna Inc said on Thursday it was partnering with contract drugmaker Catalent Inc to prepare an initial 100 million doses of its coronavirus vaccine for the United States, starting in the th...
Moderna Inc said on Thursday it was partnering with contract drugmaker Catalent Inc for filling and packaging millions of doses of its experimental coronavirus vaccine to be supplied in the Un...
Shares of Moderna Inc. MRNA, +3.01% gained 2.6% in premarket trading on Thursday after the company said that Catalent Inc.
CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a n...
The contract manufacturer will be able to supply hundreds of millions of doses of AZD1222 starting in August.
A combination of acquisitions and coronavirus vaccine manufacturing deals have pushed shares to an all-time high, but not all earnings are flowing to common stockholders.
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2020 Results - Earnings Call Transcript
It helps that the current fiscal year concludes at the end of June, but the business also remains an essential partner for the pharmaceutical industry.
About CTLT
Catalent, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jul 31, 2014 |
| CEO John R. Chiminski | Employees 13,900 |
| Stock Exchange NYSE | Ticker Symbol CTLT |
Financial Performance
In 2020, Catalent's revenue was $3.09 billion, an increase of 22.89% compared to the previous year's $2.52 billion. Earnings were $220.70 million, an increase of 60.63%.
Analyst Forecasts
According to 12 analysts, the average rating for Catalent stock is "Strong Buy." The 12-month stock price forecast is 114.90, which is a decrease of -2.86% from the latest price.